Medications

FDA panel backs Pfizer drug for kidney cancer

(AP) -- A panel of advisers to the Food and Drug Administration voted Wednesday that the benefits of a Pfizer kidney cancer drug outweigh its risks, according to a company spokeswoman.

Oncology & Cancer

Cancer-seeking 'smart bombs' target kidney cancer cells

Researchers are halting kidney cancer with a novel form of radioimmunotherapy that zeroes in on antigens associated with renal cell carcinoma. Patients with progressive kidney cancer receiving up to three doses of the therapy ...

page 19 from 19